Public health officials are issuing preliminary recommendations following reports that recent vaccine distributions included a promotional vial of inert saline, a variable that researchers warn lacks sufficient longitudinal evidence.
The FDA has initiated a preliminary review after a cohort of pharmacists in the Northeast identified a secondary, travel-sized vial shrink-wrapped to recent Moderna mRNA deliveries. According to early documentation, the supplementary vials were distinctly labeled as a “complimentary placebo” and accompanied by packaging encouraging patients to “enjoy the control group experience at no extra cost.” While early laboratory assays suggest the bonus liquid is merely sterile saltwater, regulatory bodies emphasize that a lack of active ingredients does not automatically eliminate it as a risk factor in broader patient outcomes.
While preliminary findings suggest this bonus liquid is entirely inert, we currently lack the rigorous, multi-phase clinical trials necessary to recommend injecting a recreational saline solution alongside a standard immunization.
Moderna issued a heavily caveated apology on Thursday, characterizing the inclusion as a manufacturing deviation originally intended for an internal study appreciation event. The pharmaceutical manufacturer stressed that while no causal link has been established between the complimentary saline and any adverse health outcomes, they are voluntarily recalling the promotional vials out of an abundance of methodological caution. A forthcoming JAMA paper is expected to explore whether receiving a free, medically useless injection alters surveyed patient satisfaction metrics.
At press time, the CDC updated its recommendations for affected patients, advising anyone who has already received the bonus liquid to monitor themselves closely for a complete absence of physiological changes, noting that a total lack of symptoms does not necessarily prove causation.